The in vitro diagnostic study at the cardiology department of Kurashiki Central Hospital in Okayama, Japan, was conducted to measure levels of AtherOx in healthy individuals and patients with severe cardiovascular complications. The initial results of the research study indicate that the test may identify patients at increased risk of major complications from heart disease such as heart attacks or severe chest pain.
The test kits used in the trial were developed at Corgenix using its proprietary AtherOx technology, which measures the presence of oxidized low-density lipoprotein/a2GPI complexes in patients’ blood. Further trials to confirm the initial findings of this new cardiovascular disease risk marker are scheduled in both the US and Japan over the next several years.
Katsumi Inoue, director of the Clinical Research Center at the Kurashiki Central Hospital, and principal investigator of the study, said: “The measurement of oxLDL/a2GPI complexes in patients with cardiovascular diseases provides a novel serologic marker for those patients prone or at risk for more severe complications such as heart attack or unstable chest pain.”